Flibanserin's effectiveness for low sexual desire in premenopausal women may vary based on hormone levels, with normal hormone levels showing better responses.
The conversation discusses preferences for hair loss treatments, specifically finasteride over dutasteride. Users share personal experiences, cost considerations, FDA approval status, and potential side effects, with some switching between treatments to find what works best for them.
The Phase 2 trial for Pyrilutamide in the US, which started a year after the China trials, and inquiring about any available information on when it will finish. Treatments discussed include Minoxidil, Finasteride, and RU58841.
Researching whether pyri and enza, which are stereoisomers of each other, share the same features related to CNS penetration/GABA Inhibition; safety and efficacy when used topically at 0.5-1%; and cost comparison between the two treatments.
Minoxidil 5% topical solution may cause eyesight problems, with some users experiencing blurred vision. The discussion also mentions finasteride's potential side effects, including erectile dysfunction, with varied personal experiences.
Finasteride and Dutasteride do not cause depression or "Post Finasteride Syndrome," with concerns often linked to the nocebo effect and preexisting mental health issues. The EU is unlikely to ban these drugs, but access may become more restricted due to ongoing debates.